Company intelligence / Profile preview

LB Investment

New York, New York, United States

Ownership: Private
Employees: ~16
Development stage: Other

Overview

LB Pharmaceuticals’ lead candidate LB-102, a novel derivative of amisulpride, demonstrated statistically significant improvement in schizophrenia symptoms versus placebo in a 359-patient Phase 2 trial. The Phase 3 trial for schizophrenia is scheduled to start in early 2026, with an additional Phase 2 study in bipolar depression planned. Side effects in Phase 2 were manageable, and the company aims for an NDA submission in 2028.

Therapeutic areas: NeurologyPsychiatry
Modalities: Small molecule
Industry: Investors

Beyond the preview

Go deeper on LB Investment.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LB Investment.

Explore the full profile